Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fludarabine + cyclophosphamide followed by thalidomide in angioimmunoblastic T-cell lymphoma
2005-003931-40Phase 2Completed
- Sponsor
- University College London
- Start
- Feb 2006
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fludarabine, cyclophosphamide and thalidomide in angioimmunoblastic T-cell lymphoma (AITL), sponsored by University College London. Primary endpoint: Response rate following FluCy chemotherapy. Started Feb 2006; status: completed.
02
Drugs
fludarabinecyclophosphamidethalidomide
03
Conditions
angioimmunoblastic T-cell lymphoma (AITL)
Beyond the preview
Go deeper on 2005-003931-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003931-40.